A case report on anti-tubercular agent induced hepatotoxicity
DOI:
https://doi.org/10.18203/2320-6012.ijrms20241583Keywords:
Anti-tubercular agent, Hepatotoxicity, ALT, ASTAbstract
Hepatotoxicity is the serious adverse effect of tuberculosis treatment and it leads to the discontinuation of Anti-tubercular agent (ATT) causing increased drug resistance, morbidity and mortality. We report a 69 years old male patient with ATT induced hepatotoxicity.
Metrics
References
Tostmann A, Boeree MJ, Aarnoutse RE, De Lange WC, Van Der Ven AJ, Dekhuijzen R. Antituberculosis drug‐induced hepatotoxicity: concise up‐to‐date review. J Gastroenterol Hepatol. 2008;23(2):192-202.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472-7.
Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study. Int J Mycobacteriol. 2016;5(1):14-20.
Molla Y, Wubetu M, Dessie B. Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia. J Hepatic Medicine: Evidence and Research. 2021;28(13):1-8.
Sarma GR, Immanuel C, Kailasam S. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis. 1986;133:1072-5.
Wang PY, Xie SY, Hao Q. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16:589-95.
Downloads
Published
How to Cite
Issue
Section
